AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03741075 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BUA
Description: bilateral uterine artery ligation (BUAL) after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures
Study NCT03741075 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BUA
Description: bilateral uterine artery ligation (BUAL) after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures
Study NCT03741075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical tranexamic acid
Description: topical application of 200ml saline contains 2 gm tranexamic acid to the placental bed after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures
Study NCT03741075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: topical application of 200ml saline to the placental bed after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures
Study NCT04151420 — intervention group
Intervention type: OTHER
Intervention: Remote monitoring tool (infections questionnaire) validation
Description: There will be no treatment intervention in the current study (no drugs will be used). Instead, patients are enrolled in a routine care eHealth care-pathway with myIBDcoach. MyIBDcoach (MijnIBDcoach, Dutch, Sananet Care B.V., Sittard, The Netherlands, https://www.mijnibdcoach.nl) is a web-based platform for home-monitoring and patient- provider communication in patients with IBD.~Patients already using the myIBDcoach will be informed on this study. Patients will be asked to continue routine care including monitoring of PROs through the myIBDcoach. When a patient completes the infections disease questionnaire for the first time, this will be regarded as the starting point (T=0) for this patient. Patients will complete the questionnaire every three months after the starting point as part of their routine follow-up. Results from these questionnaires will be stored electronically and will be analyzed alongside medical records of GP's and drug delivery data from pharmacies.
Study NCT01539512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idelalisib
Description: Idelalisib 150 mg tablet administered orally twice daily
Study NCT01539512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab administered intravenously 8 times through Week 20: Day 1: 375 mg/m\^2, and 500 mg/m\^2 thereafter
Study NCT01539512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Rituximab administered intravenously 8 times through Week 20: Day 1: 375 mg/m\^2, and 500 mg/m\^2 thereafter
Study NCT01957202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
Study NCT03405649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group A
Description: Muscle conditioning exercise for postpartum women and infants less than 20 weeks of age.
Study NCT03405649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group B
Description: Muscle conditioning exercise for postpartum women and infants more than 20 weeks of age.
Study NCT04780412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Vaginal Misoprostol tablets in a dose of 50 microgram given 90-120 minutes before an elective caesarian section.
Study NCT04780412 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaginal placebo pills given 90-120 minutes before an elective caesarian section.
Study NCT04395690 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Implant Placement in the posterior mandible
Description: Surgery done in the posterior mandible with missing teeth for placing dental implants.
Study NCT01539512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match idelalisib
Description: Placebo to match idelalisib administered orally twice daily
Study NCT04395690 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Implant Placement in the posterior mandible
Description: Surgery done in the posterior mandible with missing teeth for placing dental implants.
Study NCT02953574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: daily sleep enhancement nursing protocol
Study NCT01426022 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition
Description: Moderate alcohol consumption with dinner (3 glasses of sparkling white wine, containing ca. 30 g alcohol)
Study NCT01426022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mood manipulation
Description: Mood will be manipulated by changing the ambiance in either a pleasant or unpleasant way.
Study NCT02462720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varithena®
Description: Varithena® treatment in accordance with full prescribing information and instructions for use
Study NCT02462720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varithena®
Description: Varithena® treatment in accordance with full prescribing information and instructions for use
Study NCT02462720 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation conducted per physicians' standard of care.
Study NCT02462720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation conducted per physicians' standard of care.
Study NCT02496299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Comparison of analgesic effects of dexamethasone with plain bupivacaine during caudal blocks in children
Study NCT01767376 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix®
Description: One dose administered intramuscularly (IM) in the deltoid of the right arm (in Co-ad Group) and left arm (in TdapACWY and ACWYTdap Groups).
Study NCT02496299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Comparison of analgesic effects of dexamethasone with plain bupivacaine during caudal blocks in children
Study NCT00156416 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Meditation
Description: 8 weeks of meditation training
Study NCT00156416 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: 8 weeks of meditation training
Study NCT02354872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Mini-Lozenge
Description: If randomized to only the Nicotine Mini-Lozenge condition: Participants randomized to this condition will receive up to a 12 month supply of 2 mg or 4 mg nicotine mini-lozenges. Mini-Lozenges will be given at the initial visit and over the course of the whole study. Participants will be instructed to use 9 pieces daily for the 12 months.
Study NCT00705471 — intervention group
Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: None available in the protocol. This was a chart review study, therefore no Infliximab provided during the study.
Study NCT03912727 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha-Lipoic acid plus renal replacement therapy
Description: Alpha lipoic acid (ALA) is a vitamin-like antioxidant
Study NCT03912727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: renal replacement therapy
Description: standard renal replacement therapy
Study NCT03912727 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: renal replacement therapy
Description: standard renal replacement therapy
Study NCT04362917 — intervention group
Intervention type: OTHER
Intervention: There is no intervention
Description: There is no intervention
Study NCT02354872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Reduction Counseling
Description: We will deliver BR in 10 (10-15 minute) sessions over a 52-week period, with an in-person session at Visit 1 followed by nine phone counseling sessions. Sessions are front-loaded to enhance acquisition of new behaviors. BR Counseling will emphasize the development of smoking control skills via feasible, specific, and graded assignments of smoking reduction activities that will be tracked over time. BR will also emphasize competence and self-efficacy, both which will be directly linked to the practice of smoking reduction skills and success in smoking control. The health counselor will provide rationales for the reduction intervention, why reduction (e.g., eliminating smoking contexts) should help the smoker, and provide the participant with specific exercises and goals. The health counselor will explicitly address pragmatic issues such as work contexts, smoking policies, and habits that interfere with smoking reduction efforts.
Study NCT01492452 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: standardized guidelines for nursing
Description: Information was provided regarding the preoperative preparation of the child, the same conditions and in the postoperative period, as well as information relating to housing and food for the parents. The conventional orientation took about 15 minutes.
Study NCT04050111 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stromal-vascular fraction
Description: Concentrate of stromal-vascular fraction of cells derived from autologous adipose tissue
Study NCT03319160 — intervention group
Intervention type: DEVICE
Intervention: Wearable Cardioverter Defibrillator
Description: A non-invasive wearable cardioverter defibrillator detects and treats VT/VF without the need for bystander intervention
Study NCT03700762 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound gray-scale ratio
Description: RADinfo radiograph reading system was used to measure the gray-scales of PTMC, NG, and thyroid tissues at the same gain level, the UGSR values of the PTMC, NG, and thyroid tissue were calculated.
Study NCT03412331 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonic
Description: Cavitron® BOBCAT® Pro, Dentsply International, USA
Study NCT03412331 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic
Description: Cavitron® BOBCAT® Pro, Dentsply International, USA
Study NCT03412331 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hand Instruments
Description: Gracey, SG 5/6, 7/8, 11/12, 13/14, Hu-Friedy Ins. Co., USA
Study NCT02354872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5Rs Motivation Counseling
Description: The 5Rs Motivation Counseling will be delivered in four (10-15 min) sessions over a 52-week period. Participants in the on condition will receive three brief phone sessions over the year to prompt processing of motives for smoking reduction or cessation. The health counselor and smoker will discuss: 1) Relevance of smoking to the individual; 2) Risks of continued heavy smoking; 3) Rewards of quitting and significant reduction; and 4) Roadblocks to success; and will do so on a 5) Repeated basis. The discussion will follow the general principles of MI: counselors will use strategies that are nonauthoritarian, nonconfrontational, supportive, and use open-ended questions.
Study NCT02304224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eye masks
Description: eye masks from 21:00 to 6:00 each night during admission
Study NCT03688412 — intervention group
Intervention type: DEVICE
Intervention: Cook lead extraction devices
Description: The Cook lead extraction devices are mechanical devices that encompass a full variety of devices required for percutaneous removal of CIED leads, indwelling catheters and foreign objects.
Study NCT04507932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI
Description: Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of inflammatory bowel disease by PET/CT.
Study NCT03450707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine 500 mg IV
Description: Thiamine hydrochloride (vitamin B1) 500mg IV will be given every 12 hours for 5 doses in the experimental arm.
Study NCT03450707 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mL of intravenous normal saline will be given every 12hours for 5 doses in the placebo arm
Study NCT01127750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTY720
Study NCT02635464 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hUC-MSCs+Injectable collagen scaffold+CABG
Description: Patients underwent Coronary Artery Bypass Surgery (CABG) with 10\^8 allogeneic human umbilical cord mesenchymal stem cells (hUC-MSCs) in collagen scaffold injecting in the infarct region.
Study NCT02635464 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hUC-MSCs+CABG
Description: Patients underwent Coronary Artery Bypass Surgery (CABG) with 10\^8 allogeneic human umbilical cord mesenchymal stem cells (hUC-MSCs) injecting in the infarct region.
Study NCT02635464 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG
Description: Patients underwent CABG alone.
Study NCT00151814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Description: Children less than 6 years old: oral suspension or tablets equal to 0.3 mg/kg; 20 mg or 40 mg tablets for older children depending on weight.
Study NCT02644707 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-selenomethionine
Description: The group will be randomized to receive organic selenium in the form of L-selenomethionine at the dose of 200mcg daily (intervention group) for 6 months
Study NCT02644707 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The group will be randomized to receive placebo (control group) for 6 months
Study NCT03532997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ELOS
Description: The investigators aim to introduce patients with advanced cancer to supportive care resources, including specialty palliative care, through a novel web-based application called ELOS (stands for extra layer of support) in a prospective cohort study.
Study NCT02927379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline plus dexmetedomidine in two divided doses i.e. 20 ml is administered on each side of incision
Study NCT02927379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline plus ketamine in two divided doses i.e. 20 ml is administered on each side of incision
Study NCT02927379 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline only in two divided doses i.e. 20 ml is administered on each side of incision
Study NCT01895673 — intervention group
Intervention type: OTHER
Intervention: Gadolinium
Description: All patients will undergo PET-MRI additional to the PET-CT they routinely undergo. All patients will be administered Gadolinium for the PET-MRI scan. This is an extra intervention than they would normally undergo.
Study NCT01488097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sebelipase alfa
Description: Sebelipase alfa is a recombinant human lysosomal acid lipase.
Study NCT04407910 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AIRFLOW® Master device +Opalescence Xtra Boost.
Description: Prophylaxis techniques for pre-bleaching treatment
Study NCT04407910 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: rubber-cup+Opalescence Xtra Boost.
Description: Prophylaxis techniques for pre-bleaching treatment
Study NCT03999411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicoderm C-Q Transdermal Product
Description: 6 weeks of GlaxoSmithKline Nicoderm CQ (NRT)
Study NCT03999411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicoderm C-Q Transdermal Product
Description: 6 weeks of GlaxoSmithKline Nicoderm CQ (NRT)
Study NCT03999411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicoderm C-Q Transdermal Product
Description: 6 weeks of GlaxoSmithKline Nicoderm CQ (NRT)
Study NCT03999411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence to Antiretroviral Therapy Counseling
Description: Brief counseling on adhering to antiretroviral therapy with self-help materials.
Study NCT03999411 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adherence to Antiretroviral Therapy Counseling
Description: Brief counseling on adhering to antiretroviral therapy with self-help materials.
Study NCT03999411 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Adherence to Antiretroviral Therapy Counseling
Description: Brief counseling on adhering to antiretroviral therapy with self-help materials.
Study NCT03999411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Smoking Cessation Counseling
Description: One time face-to-face smoking cessation counseling and 2 follow-up phone calls.
Study NCT03999411 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Smoking Cessation Counseling
Description: One time face-to-face smoking cessation counseling and 2 follow-up phone calls.
Study NCT03999411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crave-to-Quit app
Description: Evidence-based mindfulness smoking cessation smartphone app (Crave-to-Quit) adapted from an in-person mindfulness training relapse prevention smoking cessation intervention.
Study NCT03999411 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Crave-to-Quit app
Description: Evidence-based mindfulness smoking cessation smartphone app (Crave-to-Quit) adapted from an in-person mindfulness training relapse prevention smoking cessation intervention.
Study NCT03999411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vDOT emocha app
Description: Video Directly Observed Therapy (vDOT) smartphone app (emocha) that allows participants to take a video of themselves taking medication to ensure adherence.
Study NCT03846310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant is an A2aR and A2bR antagonist
Study NCT03846310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab is a fully human anti-PD-1 monoclonal antibody
Study NCT03846310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin administered as part of standard chemotherapy regimen
Study NCT03846310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed administered as part of standard chemotherapy regimen
Study NCT03412331 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand Instruments
Description: Gracey, SG 5/6, 7/8, 11/12, 13/14, Hu-Friedy Ins. Co., USA
Study NCT03412331 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LED Source
Description: LED source (625-635 nm wavelength) (FotoSan®, CMS Dental, Denmark)
Study NCT00797082 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI = Myocardial Perfusion Stress
Study NCT00797082 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MPS
Description: MPS = Myocardial Perfusion Scintigraphy
Study NCT03976427 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Imagery
Description: The guided imagery exercise asks participants to think about positive associations with healthy foods and imagine their future healthy selves.
Study NCT01263548 — intervention group
Intervention type: DRUG
Intervention: lisdexamfetamine dimesylate
Description: Dosage form: Capsules; Dosage strength: 30-70mg/day, flexible dosing; Duration: 4 weeks
Study NCT00699010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acurox 5/30mg taken first
Description: followed by oxycodone 5mg with 48 hour washout
Study NCT00699010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone 5mg taken first
Description: followed by Acurox 5/30mg with 48 hour washout
Study NCT03557307 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab subcutaneous injection
Study NCT02416349 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory Muscles Stretching
Description: Respiratory Muscles Stretching The stretching will occur throughout the expiratory phase to allow respiratory muscles to reach their maximal length, and two sets with 10 consecutive incursions will be use for each stretching pattern with an interval of 30 seconds between series.~Pattern 1: Neck stretching Pattern 2: Upper chest stretching Pattern 3:Pectoralis major stretching Pattern 4:Lateral chest stretching
Study NCT02416349 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Control Group - all volunteers will be positioned at rest in a comfortable in a chair during 20 minutes.
Study NCT03846310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized anti-PD-1 monoclonal antibody